Rahul D. Ballal - 07 Nov 2024 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Director
Signature
/s/ William Cook, as attorney-in-fact for Rahul Ballal
Issuer symbol
AGIO
Transactions as of
07 Nov 2024
Net transactions value
-$597,347
Form type
4
Filing time
12 Nov 2024, 16:09:38 UTC
Previous filing
10 Oct 2024
Next filing
10 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $259,900 +10,000 +125% $25.99 17,992 07 Nov 2024 Direct F1
transaction AGIO Common stock Sale $433,598 -8,132 -45% $53.32 9,860 07 Nov 2024 Direct F1, F2
transaction AGIO Common stock Sale $101,638 -1,868 -19% $54.41 7,992 07 Nov 2024 Direct F1, F3
transaction AGIO Common stock Options Exercise $259,900 +10,000 +125% $25.99 17,992 08 Nov 2024 Direct F1
transaction AGIO Common stock Sale $204,404 -3,571 -20% $57.24 14,421 08 Nov 2024 Direct F1, F4
transaction AGIO Common stock Sale $288,692 -4,929 -34% $58.57 9,492 08 Nov 2024 Direct F1, F5
transaction AGIO Common stock Sale $88,815 -1,500 -16% $59.21 7,992 08 Nov 2024 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Stock option (right to buy) Options Exercise $0 -10,000 -26% $0.000000 27,947 07 Nov 2024 Common stock 10,000 $25.99 Direct F1, F7
transaction AGIO Stock option (right to buy) Options Exercise $0 -10,000 -36% $0.000000 17,947 08 Nov 2024 Common stock 10,000 $25.99 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $53.00 to $53.84. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $54.02 to $54.60. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $57.00 to $58.00. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $58.00 to $58.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $59.01 to $59.37. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F7 This option was granted on August 11, 2022. The shares underlying this option vest as to 25% of the underlying shares on August 11, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.